**EBITDA** (a)

Quarterly, fiscal 2013 to present

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>1Q</th>
<th>2Q</th>
<th>3Q</th>
<th>4Q</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017 (b)</td>
<td>$1,751</td>
<td>$1,692</td>
<td>$1,502</td>
<td>$1,812</td>
<td>$6,757</td>
</tr>
<tr>
<td>2016</td>
<td>$1,858</td>
<td>$1,818</td>
<td>$1,631</td>
<td>$1,960</td>
<td>$7,267</td>
</tr>
<tr>
<td>2015 (c)</td>
<td>$1,694</td>
<td>$1,881</td>
<td>$1,437</td>
<td>$2,731</td>
<td>$7,743</td>
</tr>
<tr>
<td>2014</td>
<td>$1,533</td>
<td>$1,560</td>
<td>$1,439</td>
<td>$2,130</td>
<td>$6,664</td>
</tr>
<tr>
<td>2013 (d)</td>
<td>$2,104</td>
<td>$1,794</td>
<td>$1,444</td>
<td>$1,823</td>
<td>$7,166</td>
</tr>
</tbody>
</table>

(a) Amounts relate to our continuing operations.
(b) The fourth quarter and full year 2017 consisted of 14 weeks and 53 weeks, respectively, compared with 13 weeks and 52 weeks in the comparable prior-year periods.
(c) Fourth quarter and full year amounts include a $620 million gain on sale of our former pharmacy and clinic businesses.
(d) First quarter and full year amounts include a $391 million gain on sale of our U.S. credit card receivables portfolio.